CC
Casdin Capital Portfolio holdings
AUM
$1.1B
This Quarter Return
+14.38%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$814M
AUM Growth
+$814M
(+15%)
Cap. Flow
+$81M
Cap. Flow
% of AUM
9.95%
Top 10 Holdings %
Top 10 Hldgs %
56.48%
Holding
38
New
4
Increased
14
Reduced
3
Closed
2
Top Buys
| 1 |
NVTA
Invitae Corporation
NVTA
|
$40.2M |
| 2 |
BioLife Solutions
BLFS
|
$25M |
| 3 |
Agios Pharmaceuticals
AGIO
|
$16.6M |
| 4 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
$11.6M |
| 5 |
GRTS
Gritstone bio, Inc. Common Stock
GRTS
|
$10.3M |
Top Sells
| 1 |
FMI
Foundation Medicine, Inc.
FMI
|
$93.6M |
| 2 |
Zai Lab
ZLAB
|
$3.14M |
| 3 |
OraSure Technologies
OSUR
|
$1.78M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$1.52M |
| 5 |
Fate Therapeutics
FATE
|
$815K |
Sector Composition
| 1 | Healthcare | 87.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
| $61.5M | 7.47% | 360,000 | – | – |
|
|
BPMC
2
DELISTED
Blueprint Medicines
BPMC
| $58.5M | 7.12% | 750,000 +115,000 | +18% | +$8.98M |
|
|
MYOK
3
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $52.5M | 6.38% | 805,000 +25,000 | +3% | +$1.63M |
|
|
4
Agios Pharmaceuticals
AGIO
$2.19B
| $44.7M | 5.43% | 579,776 +215,000 | +59% | +$16.6M |
|
|
SAGE
5
DELISTED
Sage Therapeutics
SAGE
| $44.1M | 5.36% | 312,000 +62,000 | +25% | +$8.76M |
|
|
6
BioLife Solutions
BLFS
$1.2B
| $42.5M | 5.17% | 2,428,571 +1,428,571 | +143% | +$25M |
|
|
7
Fate Therapeutics
FATE
$120M
| $41.5M | 5.05% | 2,550,000 -50,000 | -2% | -$815K |
|
|
NVTA
8
DELISTED
Invitae Corporation
NVTA
| $40.2M | 4.88% | +2,400,000 | New | +$40.2M |
|
|
BLUE
9
DELISTED
bluebird bio
BLUE
| $37.7M | 4.58% | 258,000 +58,000 | +29% | +$8.47M |
|
|
ONCE
10
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $36.8M | 4.48% | 675,000 +212,000 | +46% | +$11.6M |
|
11
Codexis
CDXS
$246M
| $34.7M | 4.22% | 2,025,000 | – | – |
|
12
Sangamo Therapeutics
SGMO
$157M
| $33.9M | 4.12% | 2,000,000 +600,000 | +43% | +$10.2M |
|
13
Dianthus Therapeutics
DNTH
$759M
| $27M | 3.29% | 2,250,818 +215,000 | +11% | +$2.58M |
|
14
Illumina
ILMN
$15.8B
| $26.2M | 3.19% | 71,500 | – | – |
|
|
GNMK
15
DELISTED
GenMark Diagnostics, Inc
GNMK
| $25.7M | 3.13% | 3,500,000 +100,000 | +3% | +$735K |
|
|
BOLD
16
DELISTED
Audentes Therapeutics, Inc
BOLD
| $24.7M | 3.01% | 625,000 +175,000 | +39% | +$6.93M |
|
17
Alnylam Pharmaceuticals
ALNY
$58.5B
| $23.6M | 2.87% | 270,000 | – | – |
|
18
Voyager Therapeutics
VYGR
$186M
| $21.5M | 2.61% | 1,135,000 | – | – |
|
|
GBT
19
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $16.7M | 2.03% | 440,000 -40,000 | -8% | -$1.52M |
|
20
Evolent Health
EVH
$1.12B
| $15.6M | 1.9% | 550,000 | – | – |
|
21
Editas Medicine
EDIT
$231M
| $14.6M | 1.78% | 460,000 +281,667 | +158% | +$8.96M |
|
|
ONC
22
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $12.1M | 1.47% | 70,000 | – | – |
|
|
GRTS
23
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $10.3M | 1.25% | +720,586 | New | +$10.3M |
|
24
CRISPR Therapeutics
CRSP
$4.71B
| $9.76M | 1.19% | 220,000 | – | – |
|
|
CNST
25
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $8.85M | 1.08% | +1,314,743 | New | +$8.85M |
|